Media Room

For More Information Contact

For Media Inquiries:

Dana Korsen
Phone:
202-334-2183
Fax:
202-334-2843
E-mail:
dkorsen@nas.edu

Mailing Address

The National Academies of Sciences, Engineering, and Medicine

Health and Medicine Division

500 Fifth St, NW
Washington, DC 20001

Selected Filters

    • Topic: Biomedical and Health Research [Remove]

Filter News

News and Announcements

The latest news from HMD, including information about new reports, activities, meetings, and other noteworthy events.


News Release

Independent Review Commends CIRM's Achievements, But Calls on Institute to Revise Governance and Policies to Maintain Credibility and Impact
Released: 12/6/2012

The California Institute for Regenerative Medicine (CIRM) has achieved many notable results during its first seven years and helped establish the state of California as an international hub of stem cell research and development, says a new report from the Institute of Medicine. However, CIRM's efforts could be enhanced by creating an external scientific advisory board to provide continuing and consistent strategic advice, by dealing more effectively with the perception of conflicts of interest on its governing board, and by reorganizing its governance to ensure that the board is able to provide independent oversight.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

Media Advisory

CIRM Review by Institute of Medicine to Release Dec. 6
Released: 12/3/2012

The California Institute for Regenerative Medicine (CIRM) asked the Institute of Medicine to conduct an independent review of CIRM's programs and operations and recommend steps to improve its performance. The results of this review appear in a new IOM report, The California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. Members of the authoring committee will discuss their findings and recommendations in a one-hour telephone press briefing beginning at 1:30 p.m. EST (10:30 a.m. PST) Thursday, Dec. 6.

Reports: Related Reports
Activities: Related Activities

Announcement

IOM Member Lefkowitz awarded Nobel Prize in Chemistry

Institute of Medicine member Robert J. Lefkowitz was awarded 2012 Nobel Prizes in Chemistry. Lefkowitz was elected to the IOM in 1994 and is also a member of the National Academy of Sciences. He received the award jointly with Brian K. Kobilka “for studies of G-protein-coupled receptors.” Lefkowitz is a professor of medicine and biochemistry at Duke University.

Reports: Related Reports
Activities: Related Activities

Media Advisory

Uses of DOD's Joint Pathology Center Biorepository: IOM Report Releases Oct. 10
Released: 10/8/2012

Future Uses of the Department of Defense Joint Pathology Center Biorepository, a new report from the Institute of Medicine, offers guidance to DOD on maintaining and managing the collection and determining appropriate uses of its samples in research, education, and consultations.

Reports: Related Reports
Activities: Related Activities

Actions Taken

NIH Creates Office of Emergency Care Research

Sparked by the release of three 2006 IOM reports – Emergency Care for Children: Growing Pains, Hospital-Based Emergency Care: At the Breaking Point, and Emergency Medical Services At the Crossroads – the NIH began an effort to examine its research activities in emergency medicine and to hear from investigators and stakeholders in the field. The IOM reports found the emergency medical system to be overburdened, underfunded, and highly fragmented. The NIH effort led to the creation in 2012 of the Office of Emergency Care Research.

Reports: Related Reports
Activities: Related Activities

News Release

Creation of a Central Management Plan for Every New Drug Needed to Strengthen FDA's Oversight of Approved Drugs' Safety
Released: 5/1/2012

Although the approval of a new drug is based on evidence that its benefits outweigh its risks, the full range of a medication's effects may not become apparent until a product has been used by a larger, more diverse population over an extended period of time. Problems associated with the anti-diabetes drug Avandia, pain reliever Vioxx, and cholesterol-reducing drug Crestor illustrate the challenges and underscore the need for a more systematic and transparent process to collect, assess, and act on data about a medication's benefit-risk profile throughout its entire "life cycle" from approval until it is no longer marketed, says a new report by the Institute of Medicine.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

Media Advisory

Studying the Safety of Approved Drugs: IOM Report Releases May 1
Released: 4/25/2012

Although drugs undergo safety tests prior to approval, sometimes harmful effects do not become apparent until a product has been on the market for a while and has been used by a larger, more diverse population.

Reports: Related Reports
Activities: Related Activities

News Release

IOM Report Recommends Evaluation and Validation Process to Prevent Problems Associated With Turning 'Omics' Research Into Clinical Tests
Released: 3/23/2012

Genomics, proteomics, and other branches of molecular bioscience offer the prospect of greater precision in medical care, but some clinical tests based on "omics" research have proved invalid and highlighted the challenges of dealing with complex data. To enhance the translation of omics-based discoveries to clinical use, a new report by the Institute of Medicine recommends a detailed process to evaluate whether the data and computational steps underlying such tests are sound and the tests are ready to be used in clinical trials. The proposed process defines responsibilities and best practices for the investigators, research institutions, funders, regulators, and journals involved in development and dissemination of clinical omics-based technologies.

Report at a Glance

Reports: Related Reports
Activities: Related Activities

Media Advisory

IOM Report on Improving “Omics-Based” Test Development Releases March 23
Released: 3/21/2012

Genomics, proteomics, and other branches of molecular bioscience offer the possibility of greater precision in medical care by tailoring therapies to patients' genetic or molecular profiles. But some clinical tests based on "omics" research, including tests developed by researchers at Duke University to select chemotherapy for cancer patients, have proved invalid. Evolution of Translational Omics: Lessons Learned and the Path Forward, a new report from the Institute of Medicine, recommends steps to help avoid future problems associated with moving omics-based discoveries from the lab to clinical settings.

Reports: Related Reports
Activities: Related Activities

Announcement

What You're Reading - February 2012

A list of the most viewed IOM reports for the month of February, 2012.

Reports: Related Reports
Activities: Related Activities